



Listen to Dr. Cohen's Forum for Evidence-Based Medicine podcast at <https://ohe.s3.amazonaws.com/jan-feb-2020-ebmf.wav>



Earn up to 1.00 CNE/CME credit per issue.

<b>Claiming credit</b>	CME/CNE credit is available. For more information, visit <a href="https://optumhealtheducation.com/ebm-forum">optumhealtheducation.com/ebm-forum</a>
<b>Activity description</b>	Practicing evidence-based medicine (EBM) is important in today's health care environment because this model of care offers clinicians a way to enrich quality, provide patient satisfaction, reduce costs and improve outcomes. A common implementation of EBM involves the use of clinical practice algorithms during medical decision-making to encourage optimal care. This widely recognized practice is designed to address the persistent problem of clinical practice variation with the help of actionable information at the point of care. These E-newsletters will enable health care professionals (HCPs) to put new EBM into practice.
<b>Target audience</b>	This activity is designed to meet the educational needs of physicians, PAs, nurses, nurse practitioners and other HCPs who have an interest in EBM.
<b>Learning objectives</b>	At the end of this educational activity, participants should be able to: <ul style="list-style-type: none"> <li>• Explore the educational content surrounding back pain as a means to advance optimal care outcomes.</li> <li>• Review pharmaceutical recommendations for the management of the new oral tetracyclines; omadacycline and sarecycline.</li> <li>• Apply medical management principles grounded in evidence-based medicine when comparing the harms, advantages, and costs from hematuria guidelines.</li> </ul>

## Accreditation statement



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by OptumHealth Education. OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

## Credit designation statements

### Nurses

The participant will be awarded up to 1.00 contact hour(s) of credit for attendance and completion of supplemental materials.

### Nurse practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.

### Physicians

OptumHealth Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### PAs

The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.

### Attendance

A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been pre-approved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization with which they wish to obtain credit.

### Provided by

This activity is provided by OptumHealth Education.

### Commercial support

This activity is supported by OptumCare.



## The New Oral Tetracyclines: Do they provide value?

In the last several years, two new oral tetracyclines (TCN) have been approved for use in the United States: omadacycline and sarecycline.

Omadacycline is an extended spectrum TCN with proven efficacy in treatment of community acquired pneumonia (CAP), skin and soft tissue infections (SSTI), and intra-abdominal infections (IAI).<sup>15</sup> It is effective for complex infections in hospitalized patients.<sup>16</sup> However, omadacycline may also have a role in treating CAP or SSTI in observation patients or outpatients. Of note, the omadacycline treatment arm of a CAP treatment trial exhibited increased mortality relative to other antibiotics.<sup>17</sup> Omadacycline is available for intravenous or oral administration, and treatment can be initiated as an infusion with a rapid change to the oral route. The economic justification for the high price of omadacycline is avoided hospital days with a more rapid transition to outpatient therapy. A treatment course of omadacycline is just under \$4000.

Sarecycline is a niche TCN approved exclusively for the treatment of the inflammatory lesions of non-nodular, moderate to severe acne vulgaris in patients over nine years of age (see table).<sup>18</sup> Sarecycline is an expensive orally administered agent with a relatively limited therapeutic success in the treatment of acne vulgaris. There are no available data comparing outcomes in treating acne with doxycycline vs sarecycline. The yearly cost is over \$10,000.

All tetracyclines, including these new agents, are bacteriostatic, meaning they prevent bacterial replication. This static activity can adversely affect the bacteriocidal activity of other antibiotics administered in conjunction with tetracyclines. For example, the addition of tetracyclines to penicillins has resulted in worse outcomes. Many tetracyclines have the potential of permanently staining developing teeth and should be avoided in children under the age of eight years. Tetracyclines all maintain activity against atypical organisms and in some instances they are the best treatment option (e.g., Rickettsia rickettsia the causative agent for Rocky Mountain Spotted Fever).

In summary, omadacycline retains the coverage common to all tetracyclines but offers greater efficacy against resistant gram negative and gram positive organisms. It has potential application in both inpatient and outpatient settings for CAP and SSTI. Currently, its high cost limits its application in the general population. Sarecycline is extremely expensive and has only modest treatment success for treatment of the inflammatory lesions of non-nodular, moderate to severe acne. Consider carefully the use of these new agents based on the reports of increased mortality associated with the use of omadacycline, treatment failures, higher cost and possible interactions with bacteriocidal agents.

### Approved Indications, Efficacy and Cost of Select Tetracyclines

	Approved indications				Clinical efficacy (sensitive in vitro)					cost/day (\$)
	CAP	SSTI	IAI	Acne	Atypicals	VRE	MSSA	MRSA	RGNR	
<b>Omadacycline</b>	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	475
<b>Sarecycline</b>	No	No	No	Yes	na	na	na	na	na	30
<b>Doxycycline</b>	Yes	Yes	No	Yes	Yes	No	Yes	No	No	4

Atypicals – refers to the broad array of organisms (eg, Parasites, Rickettsia species, Mycoplasma ); VRE – Vancomycin Resistant Enterococci; MSSA – Methicillin Sensitive Staphylococcus; MRSA – Methicillin Resistant Staphylococcus; RGNR – Resistant gram-negative rods; na – not available

15. Chambers, H. F. (2019). Omadacycline- The newest tetracycline. NEJM, 380(6), 588-589. doi:10.1056/NEJMe1900188

16. Burgos, R. M., & Rodvold, K. A. (2019). Omadacycline: A novel aminomethyl tetracycline. Infection and Drug Resistance, 12, 1895-1915. doi:10.2147/IDR.S171352

17. Stets, R., Popescu, M., Gonong, J. R., Mitha, I., Nseir, W., Madej, A., . . . Eckburg, P. B. (2019). Omadacycline for community-acquired bacterial pneumonia. NEJM, 380, 517-527. doi:10.1056/NEJMoa1800201

18. Deeks, E. D. (2019). Sarecycline: First global approval. Drugs, 79(3), 325-329. doi:10.1007/s40265-019-1053-4



## Comparison of Harms, Advantages, and Costs from Hematuria Guidelines

As many as two million Americans are referred to urologists annually for a finding of gross or microscopic hematuria.<sup>19</sup> Although several guidelines address the clinical evaluation of urinary tract cancers when hematuria is present,<sup>20, 21, 22, 23, 24</sup> each guideline varies in terms of the recommended testing modalities (cystoscopy, ultrasonography, computed tomography [CT] urography) and the risk factors that warrant testing. The Table lists five guidelines, ordered from least aggressive testing recommendations (Dutch, top) to most aggressive (American Urologic Association [AUA], bottom). The Dutch guidelines, for example, recommend cystoscopy and ultrasonography as the initial evaluation for hematuria, but only in patients 50 years of age and older, whereas the AUA guidelines endorse uniform cystoscopy and CT evaluations for patients with hematuria aged 35 years and older.

Georgieva and colleagues<sup>25</sup> conducted a microsimulation that compared the potential advantages, harms, and costs of the five guidelines listed in the Table. The simulation used published prospective hematuria cohort studies to model data about patient age, sex, cancer risk factors (e.g., smoking status and gross hematuria), and prevalence of urinary tract cancer (bladder, renal cell carcinoma, and upper-tract urothelial carcinoma). The cohort included 100,000 hypothetical patients,  $\geq 35$  years old.

The investigators found that cancer detection rates increased in parallel with more aggressive evaluations. But aggressive evaluations, especially uniform CT imaging, also led to more

radiation-induced cancers, more false-positive cancer diagnoses, more procedural complications, and higher monetary costs per evaluation. The Table provides detailed simulated cancer detection rates and potential harms and costs for each published guideline. Since the Dutch and Canadian Urologic Association guidelines do not include CT as part of the initial evaluation, no secondary cancers developed in those cohorts.

It is helpful to compare the AUA and Kaiser Permanente (KP) guidelines as these two are the most frequently used in the US. For the simulated population of 100,000 patients, the AUA guideline compared to the KP guideline would diagnose an additional 48 cancers while causing:

- 467 radiation induced cancers
- 13,000 additional false positive findings
- 3200 additional cases of contrast nephropathy
- Cost to diagnose one additional cancer close to \$900,000

Additionally, the microsimulation cost calculations did not include potential downstream costs associated with further testing for patients with false-positive diagnoses or with potential incidental findings from abdominal and pelvic CT scanning. Incidental findings can be seen from abdominal and pelvic CT in up to 30% of patients.<sup>26</sup>

These data suggest that the routine use of CT for all cases of microscopic hematuria per the AUA guidelines is both harmful and cost-ineffective compared to the more conservative KP guideline. The approach to initial testing of patients with hematuria should incorporate both the patients' risk factors for cancer as well as potential harms from testing. Based on the results of this study, it is reasonable to not perform CT urography as an initial screening test for patients with microscopic hematuria, especially when they are at low risk of cancer.

Table. Microsimulation estimated cancer detection rates, harms, and costs associated with hematuria guideline recommendations

Guidelines	Testing recommendations	Cancer detection rates	Radiation-associated cancers (n)	False-positives (n)	Procedural complications <sup>1</sup>	Cost in millions, US dollars
Dutch	Cystoscopy and renal ultrasonography for patients $\geq 50$ years	92.9%	0	6,452	7,999	\$44.3
Canadian Urologic Association	Cystoscopy and renal ultrasonography for patients $\geq 40$ years	95.1%	0	6,740	8,344	\$46.2
Kaiser Permanente	Cystoscopy and renal ultrasonography only with cancer risk factors; <sup>2</sup> CT and cystoscopy with gross hematuria; no evaluation without risk factors	96.3%	108	9,099	9,582	\$51.9
Hematuria Risk Index	Cystoscopy and renal ultrasonography with moderate cancer risk; CT and cystoscopy with high risk; no evaluation if low risk	96.7%	136	13,811	9,709	\$59.8
American Urologic Association	Cystoscopy and CT for patients $\geq 35$ years	97.7%	575	22,189	17,637	\$93.9

<sup>1</sup>CT contrast allergy, contrast nephropathy, dysuria, urinary tract infections

<sup>2</sup>Smokers, male sex,  $\geq 50$  years

19. David, S. A., Patil, D., Alemozaffar, M., Issa, M. M., Master, V. A., & Filson, C. P. (2017). Urologist use of cystoscopy for patients presenting with hematuria in the United States. *Urology*, 100, 20-26. doi:10.1016/j.urology.2016.09.018
20. Loo, R. K., Lieberman, S. F., Slezak, J. M., Landa, H. M., Mariani, A. J., Nicolaisen, G., . . . Jacobson, S. J. (2013). Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. *Mayo Clinic Proceedings*, 88(2), 129-138. doi:10.1016/j.mayocp.2012
21. Wollin, T., Laroche, B., & Psooy, K. (2009). Canadian guidelines for the management of asymptomatic microscopic hematuria in adults. *Canadian Urological Association journal*, 3(1), 77-80. doi:10.5489/cuaj.1029
22. van der Molen, A. J., & Hovius, M. C. (2012). Hematuria: A problem-based imaging algorithm illustrating the recent Dutch guidelines on hematuria. *American Journal of Roentgenology*, 198(6), 1256-1265. doi:10.2214/AJR.11.8255
23. Davis, R.; Jones, J S; Barocas, D A; Castle, E P; Lang, E K; Leveillee, R J; Messing, E M; Miller, S D; Peterson, A C; Turk, T M; Weitzel, W; American Urological Association. (2012). Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. *Journal of Urology*, 188(6 Suppl), 2473-2481. doi:10.1016/j.juro.2012.09.078
24. Kaiser Permanente Southern California. Standardized Hematuria Evaluation Clinical Reference [guideline]. Pasadena, CA: Southern California Permanente Medical Group; 2012.
25. Georgieva MV, Wheeler SB, Erim D, et al. Comparison of the Harms, Advantages, and Costs Associated With Alternative Guidelines for the Evaluation of Hematuria. *JAMA Intern Med*. 2019 Jul 29. doi: 10.1001/jamainternmed.2019.2280
26. Lumberras, B., Donat, L., & Hernandez-Aguado, I. (2010). Incidental findings in imaging diagnostic tests: A systematic review. *British Journal of Radiology*, 82(988), 276-289. doi:10.1259/bjr/98067945



### **Kenneth Roy Cohen, MD, FACP** | *Chief Medical Officer*

Dr. Kenneth Cohen is an experienced physician leader, practicing internist, and researcher who has attained national recognition for health care quality improvement. He has successfully developed and reported numerous clinical quality studies in primary care, including tobacco cessation, osteoporosis, asthma, diabetes, hypertension, and ischemic vascular disease. He was one of the founding physicians of New West Physicians, which is the largest primary care group practice in Colorado and now part of OptumCare. He has served as Chief Medical Officer since 1995. Dr. Cohen has received awards of recognition and distinction for teaching, including the Lutheran Medical Center Physician of the Year award in 2011. Under his stewardship New West Physicians was awarded the AMGA Acclaim award in 2015 and the Million Hearts Hypertension Champion Award in 2017. He is a Clinical Associate Professor of Medicine and Pharmacy at the University of Colorado School of Medicine. Dr. Cohen holds degrees from Dickinson College and Hahnemann University. He is a Fellow of the American College of Physicians and a member of the Phi Beta Kappa and Alpha Omega Alpha honor societies.



### **John Hitt, MD, MBA** | *Senior Medical Director*

Dr. Hitt has been a physician executive for more than 25 years. Most recently he was the CMO of Ativa Medical a medical device startup company and an independent health care consultant. Previously, he was CMO at Maricopa Integrated Health System (MIHS) and a key member of the senior leadership team having responsibility for Medical Staff Services, Grants and Research, Academic Affairs, Risk Management, physician contracted services and the activity of Residency Program Directors, Clinical Department Chairs, and Medical Staff.

Dr. Hitt has over 25 years of experience in quality and performance improvement, clinical integration, academic and medical staff affairs. He served as the Chief Medical Quality Officer for Hennepin Health System, a premier Level 1 Adult and Pediatric Trauma Center. He was a physician leader for VHA (now Vizient). He was the national Medical Director for Disease Management at Caremark International and the VP of Medical Affairs at the University of Minnesota Hospital.

Dr. Hitt is a graduate of the Univ of Virginia where he played division one soccer. He received his Medical Doctorate from the Medical College of Georgia in 1984 (AOA honors) and completed his Internal Medicine and Infectious Disease Fellowship training at the Univ of Minnesota Hospital and Clinics. Dr. Hitt completed his MBA at the Carlson School of Management at the Univ of Minnesota in 2003. He is the proud father of seven children.



### **Geoffrey Heyer, MD** | *Senior Clinical Practice Performance Consultant*

Dr. Heyer is board certified in neurology with special certification in child neurology and in headache medicine. Prior to joining our team, Dr. Heyer was an associate professor of neurology and pediatrics at The Ohio State University and Columbia University Medical Center, specializing in autonomic disorders, headache, and pain management. He has published over 50 peer-reviewed research papers and numerous editorials, clinical reviews, and textbook chapters. He also co-authored a textbook on childhood stroke and cerebrovascular disorders.

Dr. Heyer received his medical degree from Columbia University, College of Physicians and Surgeons. He completed his neurology and child neurology residencies at Columbia-Presbyterian Medical Center. He has additional research training from the Mailman School of Public Health, Columbia University.

This information is for informational purposes and should only be used by trained clinicians to aid in improving diagnosis, detection and/or clinically appropriate treatment; this information is not a substitute for clinical decision-making and should not be used to make individualized diagnostic or treatment decisions for specific patients.